![]() |
市场调查报告书
商品编码
1541627
人工授精市场报告按类型(子宫内、子宫颈内、阴道内、输卵管内)、来源类型(AIH-丈夫、AID-捐赠者)、最终用途(医院和诊所、生育中心等)和地区2024-2032Artificial Insemination Market Report by Type (Intrauterine, Intracervical, Intravaginal, Intratubal), Source Type (AIH-Husband, AID-Donor), End Use (Hospitals and Clinics, Fertility Centers, and Others), and Region 2024-2032 |
IMARC Group年,全球人工授精市场规模达21亿美元。不断上升的不孕率、快速的生活方式改变以及不断上升的医疗状况是推动市场发展的一些关键因素。
人工授精是一种受精过程,涉及透过医疗程序将精子直接放入女性生殖系统。它通常涉及使用新鲜或冷冻精子,并且可以透过多种方式完成,包括子宫颈内、子宫内或阴道内方法。人工授精的组成部分包括精液采集、精液处理和精液放置。人工授精可以增加受孕机会,降低性传染感染 (STI) 的风险,并且可以在男性不孕的情况下使用捐赠者的精子。此外,与体外受精(IVF)相比,人工授精具有微创性(MI)且具成本效益。目前,该程序有两种主要类型,包括同源和异源。同源授精涉及使用男性伴侣的精子使女性伴侣的卵子受精,而异源授精涉及使用捐赠者的精子使女性伴侣的卵子受精。
不断增加的不孕率和对辅助生殖技术(ART)的需求是推动市场成长的一些关键因素。生活方式的快速改变和多囊性卵巢症候群(PCOS)和子宫内膜异位症等疾病的盛行率不断上升,增加了对人工授精手术的需求,进一步加速了市场成长。新兴经济体对人工授精的接受度和可近性的不断提高进一步支持了这一点。此外,各种技术进步,例如精子和卵子选择、冷冻保存和植入前基因检测改进技术的发展,正在推动市场成长。除此之外,捐赠精子和捐赠卵子的可用性、同性婚姻和 LGBT 育儿的日益普及以及医疗基础设施的改善预计将推动市场成长。此外,有利法规的存在、对不孕症和人工授精的认识和教育活动不断增强,以及对个人化和客製化人工授精程序的需求不断增加,都推动了市场的成长。其他因素,例如提供人工授精服务的诊所和医疗机构数量的增加、该手术的保险覆盖范围以及推迟分娩和追求职业目标的趋势激增,都积极支持了市场的成长。
The global artificial insemination market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. Increasing infertility rates, rapid lifestyle changes, and escalating prevalence of medical conditions represent some of the key factors driving the market.
Artificial insemination is a process of fertilization that involves the placement of sperm directly into the female reproductive system through medical procedures. It typically involves the use of either fresh or frozen sperm and can be done in a variety of ways, including intracervical, intrauterine, or intravaginal methods. The components of artificial insemination include semen collection, semen processing, and semen placement. Artificial insemination offers increased chances of conception, reduced risk of sexually transmitted infections (STIs), and the ability to use donor sperm in cases of male infertility. Additionally, as compared to in vitro fertilization (IVF), artificial insemination is minimally invasive (MI) and cost-effective. Currently, there are two primary types of the procedure, including homologous and heterologous. Homologous insemination involves using the male partner's sperm to fertilize the female partner's egg, while heterologous insemination involves using donor sperm to fertilize the female partner's egg.
The increasing infertility rates and the need for assisted reproductive technologies (ART) are some of the key factors boosting the market growth. The rapid lifestyle changes and escalating prevalence of medical conditions, such as polycystic ovary syndrome (PCOS) and endometriosis, have surged the demand for artificial insemination procedures, further accelerating the market growth. This is further supported by the growing acceptance and accessibility of artificial insemination in emerging economies. Moreover, various technological advancements, such as the development of improved techniques for sperm and egg selection, cryopreservation, and pre-implantation genetic testing, are propelling the market growth. Besides this, the availability of donor sperm and donor eggs, the rising popularity of same-sex marriage and LGBT parenting, and the improving healthcare infrastructure are factors expected to drive the market growth. Furthermore, the presence of favorable regulations, the growing awareness and education campaigns about infertility and artificial insemination, and the escalating demand for personalized and customized artificial insemination procedures are fueling the market growth. Other factors, such as the increasing number of clinics and healthcare facilities offering artificial insemination services, the availability of insurance coverage for the procedure, and the surging trend of delaying childbirth and pursuing career goals, are positively supporting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial insemination market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, source type and end use.
Intrauterine
Intracervical
Intravaginal
Intratubal
The report has provided a detailed breakup and analysis of the global artificial insemination market based on the type. This includes intrauterine, intracervical, intravaginal, and intratubal. According to the report, the intrauterine segment dominates the market.
AIH-Husband
AID-Donor
The report has provided a detailed breakup and analysis of the global artificial insemination market based on the source type. This includes AIH-husband and AID-donor.
Hospitals and Clinics
Fertility Centers
Others
The report has provided a detailed breakup and analysis of the global artificial insemination market based on the end use. This includes hospitals and clinics, fertility centers, and others. According to the report, the fertility centers segment spearheads the market.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. As per the report, North America dominates the market. Some of the factors accelerating the North America artificial insemination market include the surging awareness regarding the advantages of artificial insemination, the rising consumer per capita expenditure, and burgeoning healthcare expenditure.
The report has also provided a comprehensive analysis of the competitive landscape in the global artificial insemination market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women's Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC, Vitrolife AB, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.